FR2908658B1 - Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12 - Google Patents

Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12

Info

Publication number
FR2908658B1
FR2908658B1 FR0610136A FR0610136A FR2908658B1 FR 2908658 B1 FR2908658 B1 FR 2908658B1 FR 0610136 A FR0610136 A FR 0610136A FR 0610136 A FR0610136 A FR 0610136A FR 2908658 B1 FR2908658 B1 FR 2908658B1
Authority
FR
France
Prior art keywords
overexpression
tnf
prevention
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0610136A
Other languages
English (en)
Other versions
FR2908658A1 (fr
Inventor
Ryffel Valerie Quesniaux
Germain Puzo
Jerome Nigou
Martine Gilleron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR0610136A priority Critical patent/FR2908658B1/fr
Priority to EP07870304A priority patent/EP2091544A2/fr
Priority to PCT/FR2007/001898 priority patent/WO2008068429A2/fr
Priority to US12/515,450 priority patent/US20100048492A1/en
Priority to JP2009537673A priority patent/JP2010510298A/ja
Priority to CA002670001A priority patent/CA2670001A1/fr
Publication of FR2908658A1 publication Critical patent/FR2908658A1/fr
Application granted granted Critical
Publication of FR2908658B1 publication Critical patent/FR2908658B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
FR0610136A 2006-11-20 2006-11-20 Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12 Expired - Fee Related FR2908658B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0610136A FR2908658B1 (fr) 2006-11-20 2006-11-20 Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12
EP07870304A EP2091544A2 (fr) 2006-11-20 2007-11-20 Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12
PCT/FR2007/001898 WO2008068429A2 (fr) 2006-11-20 2007-11-20 Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12
US12/515,450 US20100048492A1 (en) 2006-11-20 2007-11-20 Composition for the prevention and/or treatment of diseases associated with tnf and/or il-12 overexpression
JP2009537673A JP2010510298A (ja) 2006-11-20 2007-11-20 Ｔｎｆおよびｉｌ−１２のうちの少なくとも一方の過剰発現に関連する疾病の予防または治療のための組成物
CA002670001A CA2670001A1 (fr) 2006-11-20 2007-11-20 Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610136A FR2908658B1 (fr) 2006-11-20 2006-11-20 Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12

Publications (2)

Publication Number Publication Date
FR2908658A1 FR2908658A1 (fr) 2008-05-23
FR2908658B1 true FR2908658B1 (fr) 2011-11-11

Family

ID=38008145

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0610136A Expired - Fee Related FR2908658B1 (fr) 2006-11-20 2006-11-20 Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12

Country Status (6)

Country Link
US (1) US20100048492A1 (fr)
EP (1) EP2091544A2 (fr)
JP (1) JP2010510298A (fr)
CA (1) CA2670001A1 (fr)
FR (1) FR2908658B1 (fr)
WO (1) WO2008068429A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2931480B1 (fr) * 2008-05-23 2016-04-01 Centre Nat Rech Scient Analogues synthetiques de phosphatidyl-myo-inositol mannosides pourvus d'une active inhibitrice de la reponse inflammatoire
CN102171384B (zh) * 2008-05-28 2013-12-25 乔治洛德方法研究和开发液化空气有限公司 碳化硅基抗反射涂层
US8766177B2 (en) 2010-10-11 2014-07-01 University Of North Texas Nanomanipulation coupled nanospray mass spectrometry (NMS)
ITRM20120473A1 (it) 2012-10-04 2014-04-05 Consiglio Nazionale Ricerche Use of glycerophosphoinositols for the treatment of septic shock
BR112019022686A2 (pt) * 2017-05-05 2020-05-19 Huvepharma sacarídeos funcionalizados como agentes anti-inflamatórios
US20220257621A1 (en) * 2019-05-13 2022-08-18 Showa Denko K.K. Cancer cell proliferation suppression agent and composition for suppressing proliferation of cancer cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2596651B1 (fr) * 1986-04-08 1989-11-10 Centre Nat Rech Scient Nouveaux liposomes a base de phosphatidylinositolmannosides, et compositions pharmaceutiques les contenant
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
GB9203039D0 (en) * 1992-02-13 1992-03-25 Univ London Treatment
USRE40596E1 (en) * 1993-04-08 2008-12-02 Novartis Ag Rapamycin assay
GB9307491D0 (en) * 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
FR2792205B1 (fr) * 1999-04-19 2001-07-27 Inst Nat Sante Rech Med Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
CA2440744C (fr) * 2001-03-15 2009-12-08 Seikagaku Corporation Agent de regulation d'expression d'il-12
DE60236805D1 (de) * 2001-08-03 2010-08-05 Nat Res Council Canada Ottawa Aus mycobacterium extrahierbaren lipide hergestellete liposomen
EP1469007A1 (fr) * 2003-04-18 2004-10-20 Centre National De La Recherche Scientifique (Cnrs) Antigènes sulfoglycolipides, leur extraction de mycobacterium tuberculosis, et leur utilisation contre la tuberculose
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids

Also Published As

Publication number Publication date
WO2008068429A3 (fr) 2008-07-31
FR2908658A1 (fr) 2008-05-23
EP2091544A2 (fr) 2009-08-26
CA2670001A1 (fr) 2008-06-12
WO2008068429A2 (fr) 2008-06-12
US20100048492A1 (en) 2010-02-25
JP2010510298A (ja) 2010-04-02

Similar Documents

Publication Publication Date Title
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
FR2869541B1 (fr) Utilisation d'une composition comprenant du d-mannoheptulose et/ou du perseitol dans le traitement et la prevention des maladies liees a une modification de l'immunite innee
FR2882654B1 (fr) Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
IL182643A0 (en) Novel composition and methods for the treatment of immune related diseases
IL191772A0 (en) Compounds for the treatment of inflammatory disorders and microbial diseases
IL191637A0 (en) Compounds for the treatment of inflammatory disorders and microbial diseases
GB0412753D0 (en) Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis
EP1711197A4 (fr) Methodes et compositions pour la prevention et le traitement de maladies ou de troubles inflammatoires
FR2908658B1 (fr) Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12
ZA200800981B (en) Use of SDF-1 for the treatment and/or prevention of neurological diseases
MA29085B1 (fr) Agent prophylactique ou thérapeutique pour le traitement des troubles du sommeil
IL178903A0 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
FR2919187B1 (fr) Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie.
EP2010215A4 (fr) Utilisations et compositions pour le traitement de la maladie de crohn
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
EP1843781A4 (fr) Composition pour la prevention, le traitement et le diagnostic de maladies chroniques inflammatoires des voies aeriennes
FR2889068B1 (fr) Nouvelles fractions proteiques laitieres et leur utilisation pour la prevention ou le traitement des maladies inflammatoires chroniques
DZ3225A1 (fr) Methode et compositions pour le traitement des maladies pulmonaires
FR2924593B1 (fr) Plaque osseuse pour le traitement de l'extremite inferieure du cubitus
FR2872507B1 (fr) Composition de traitement d'une vitroceramique pour en ameliorer la resistance mecanique par guerison des defauts de surface, procedes de traitement correspondants et vitroceramiques traitees obtenues
FR2906469B1 (fr) Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques chez l'homme
FR2869539B1 (fr) Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose
HK1101674A1 (en) Composition for the prevention and treatment of allergic inflammatory disease
FR2887456B1 (fr) "composition pour le traitement de la dermite estivale"

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140731